-
1Academic Journal
المؤلفون: P. A. Gervas, A. Yu. Molokov, A. A. Zarubin, A. A. Ivanova, D. G. Tikhonov, N. S. Kipriyanova, A. N. Egorov, L. D. Zhuikova, N. A. Shefer, E. B. Topolnitskiy, V. A. Belyavskaya, L. F. Pisareva, E. L. Choynzonov, N. V. Cherdyntseva, П. А. Гервас, А. Ю. Молоков, А. А. Зарубин, А. A. Иванова, Д. Г. Тихонов, Н. С. Киприянова, А. Н. Егоров, Л. Д. Жуйкова, Н. А. Шефер, Е. Б. Топольницкий, В. А. Белявская, Л. Ф. Писарева, Е. Л. Чойнзонов, Н. В. Чердынцева
المساهمون: The study was funded by the Russian Science Foundation, project № 22-25-20032, The Core Facility «Medical genomics», Tomsk NRMC., Исследование выполнено при финансовой поддержке РНФ, проект № 22-25-20032, Оборудование ЦКП «Медицинская геномика» Томского НИМЦ.
المصدر: Siberian journal of oncology; Том 21, № 4 (2022); 72-79 ; Сибирский онкологический журнал; Том 21, № 4 (2022); 72-79 ; 2312-3168 ; 1814-4861 ; 10.21294/1814-4861-2022-21-4
مصطلحات موضوعية: PALB2, breast cancer, Asian ancestry ethnic groups in Russia, Yakut, рак молочной железы, этносы России азиатского происхождения, якуты
وصف الملف: application/pdf
Relation: https://www.siboncoj.ru/jour/article/view/2235/1009; Gifoni A.C.L.V.C., Gifoni M.A.C., Wotroba C.M., Palmero E.I., Costa E.L.V., Dos Santos W., Achatz M.I. Hereditary Breast Cancer in the Brazilian State of Ceará (The CHANCE Cohort): Higher-Than-Expected Prevalence of Recurrent Germline Pathogenic Variants. Front Oncol. 2022; 12. doi:10.3389/fonc.2022.932957.; Plon S.E., Eccles D.M., Easton D., Foulkes W.D., Genuardi M., Greenblatt M.S., Hogervorst F.B., Hoogerbrugge N., Spurdle A.B., Tavtigian S.V.; IARC Unclassified Genetic Variants Working Group. Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results. Hum Mutat. 2008; 29(11): 1282–91. doi:10.1002/humu.20880.; Richards S., Aziz N., Bale S., Bick D., Das S., Gastier-Foster J., Grody W.W., Hegde M., Lyon E., Spector E., Voelkerding K., Rehm H.L.; ACMG Laboratory Quality Assurance Committee. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015; 17(5): 405–24. doi:10.1038/gim.2015.30.; Kononova S., Vinokurova D., Barashkov N.A., Semenova A., Sofronova S., Oksana S., Tatiana D., Struchkov V., Burtseva T., Romanova A., Fedorova S. The attitude of young people in the city of Yakutsk to DNA-testing. Int J Circumpolar Health. 2021; 80(1). doi:10.1080/22423982.2021.1973697.; Kirillina M.P., Loskutova K.S., Lushnikova E.L., Nepomnyashchikh L.M. Expression of molecular biological markers in breast cancer under conditions of the Sakha Republic (Yakutia). Bull Exp Biol Med. 2014; 157(5): 623–7. doi:10.1007/s10517-014-2630-x.; Писарева Л.Ф., Одинцова И.Н., Иванов П.М., Николаева Т.И. Особенности заболеваемости раком молочной железы коренного и пришлого населения Республики Саха (Якутия). Сибирский онкологический журнал. 2007; (3): 69–72.; Eccles D.M. Hereditary cancer: guidelines in clinical practice. Breast and ovarian cancer genetics. Ann Oncol. 2004; 15(4): 133–8. doi:10.1093/annonc/mdh917.; Slatko B.E., Gardner A.F., Ausubel F.M. Overview of Next-Generation Sequencing Technologies. Curr Protoc Mol Biol. 2018; 122(1): 59. doi:10.1002/cpmb.59.; Van der Auwera G.A., Carneiro M.O., Hartl C., Poplin R., Del Angel G., Levy-Moonshine A., Jordan T., Shakir K., Roazen D., Thibault J., Banks E., Garimella, K.V., Altshuler D., Gabriel S., DePristo M.A. From FastQ data to high confidence variant calls: the Genome Analysis Toolkit best practices pipeline, Curr Protoc Bioinformatics. 2013; 43(1110): 11.10.1–11.10.33. doi:10.1002/0471250953.bi1110s43.; DePristo M.A., Banks E., Poplin R., Garimella K.V., Maguire J.R., Hartl C., Philippakis A.A., del Angel G., Rivas M.A., Hanna M., McKenna A., Fennell T.J., Kernytsky A.M., Sivachenko A.Y., Cibulskis K., Gabriel S.B., Altshuler D., Daly M.J. A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nature genetics. 2011; 43(5): 491–8. doi:10.1038/ng.806.; McKenna A., Hanna M., Banks E., Sivachenko A., Cibulskis K., Kernytsky A., Garimella K., Altshuler D., Gabriel S., Daly M., DePristo M.A. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 2010; 20(9): 1297–303. doi:10.1101/gr.107524.110.; Adzhubei I.A., Schmidt S., Peshkin L., Ramensky V.E., Gerasimova A., Bork P., Kondrashov A.S., Sunyaev S.R. A method and server for predicting damaging missense mutations. Nat Methods. 2010; 7(4): 248–9. doi:10.1038/nmeth0410-248.; Schwarz J.M., Cooper D.N., Schuelke M., Seelow D. Mutation-Taster2: mutation prediction for the deep-sequencing age. Nat Methods. 2014; 11(4): 361–2. doi:10.1038/nmeth.2890.; Kumar P., Henikoff S., Ng P.C. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat Protoc. 2009; 4(7): 1073–81. doi:10.1038/nprot.2009.86.; Richards C.S., Bale S., Bellissimo D.B., Das S., Grody W.W., Hegde M.R., Lyon E., Ward B.E.; Molecular Subcommittee of the ACMG Laboratory Quality Assurance Committee. ACMG recommendations for standards for interpretation and reporting of sequence variations: Revisions 2007. Genet Med. 2008; 10(4): 294–300. doi:10.1097/GIM.0b013e31816b5cae.; Hofstatter E.W., Domchek S.M., Miron A., Garber J., Wang M., Componeschi K., Boghossian L., Miron P.L., Nathanson K.L., Tung N. PALB2 mutations in familial breast and pancreatic cancer. Fam Cancer. 2011; 10(2): 225–31. doi:10.1007/s10689-011-9426-1.; Tischkowitz M.D., Sabbaghian N., Hamel N., Borgida A., Rosner C., Taherian N., Srivastava A., Holter S., Rothenmund H., Ghadirian P., Foulkes W.D., Gallinger S. Analysis of the gene coding for the BRCA2-interacting protein PALB2 in familial and sporadic pancreatic cancer. Gastroenterology. 2009; 137(3): 1183–6. doi:10.1053/j.gastro.2009.06.055.; Jones S., Hruban R.H., Kamiyama M., Borges M., Zhang X., Parsons D.W., Lin J.C., Palmisano E., Brune K., Jaffee E.M., Iacobuzio-Donahue C.A., Maitra A., Parmigiani G., Kern S.E., Velculescu V.E., Kinzler K.W., Vogelstein B., Eshleman J.R., Goggins M., Klein A.P. Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science. 2009; 324(5924): 217. doi:10.1126/science.1171202.; Slater E.P., Langer P., Niemczyk E., Strauch K., Butler J., Habbe N., Neoptolemos J.P., Greenhalf W., Bartsch D.K. PALB2 mutations in European familial pancreatic cancer families. Clin Genet. 2010; 78(5): 490–4. doi:10.1111/j.1399-0004.2010.01425.x.; Hanenberg H., Andreassen P.R. PALB2 (partner and localizer of BRCA2). Atlas Genet Cytogenet Oncol Haematol. 2018; 22(12): 484–90. doi:10.4267/2042/69016.; Practice Bulletin No 182: Hereditary Breast and Ovarian Cancer Syndrome. Obstet Gynecol. 2017; 130(3): 110–26. doi:10.1097/AOG.0000000000002296.; Grellety T., Peyraud F., Sevenet N., Tredan O., Dohollou N., Barouk-Simonet E., Kind M., Longy M., Blay J.Y., Italiano A. Dramatic response to PARP inhibition in a PALB2-mutated breast cancer: moving beyond BRCA. Ann Oncol. 2020; 31(6): 822–3. doi:10.1016/j.annonc.2020.03.283.; https://www.siboncoj.ru/jour/article/view/2235